This event has ended. Showing historical data.

GroupKALSHI

Event GroupKALSHIScience and Technology

Will the FDA approve gedatolisib for advanced breast cancer?

Total Volume

$0.00

Events

Markets

Trade on Kalshi

Will the FDA approve gedatolisib for advanced breast cancer?

Vol

$0.00

Events

Markets

Kalshi

Platform StatsQuick Platform Comparison

Polymarket

markets · $0.00

Kalshi

markets · $0.00

Price Spread

0.0%avg

max 0.0%

Arbitrage

of 0 cross-platform

Price ChartMatched Markets Price Graph

4 markets tracked

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jul 1, 2027?

No data available

Single-Platform Markets(4)

Market	Platform	Price
Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jul 1, 2027?	Kalshi	87%
Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Aug 1, 2026?	Kalshi	85%
Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jan 1, 2027?	Kalshi	78%
Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Oct 1, 2026?	Kalshi	78%

AI Analysis

Trader mode: Actionable analysis for identifying opportunities and edge

87%

Top Probability

$0.00

Volume

Markets

Platforms

About This Event

gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer If the FDA approves gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer for marketing before X 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application, NDA, or Biologics License Application, BLA, For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA, sNDA, or supplemental BLA, sBLA, for the sp

AI-generated analysis based on market data. Not financial advice.

Custom AI Analysis Prompt

Tap to expand

Open in:ChatGPT Claude Gemini Grok DeepSeek

**Role:** Expert Prediction Market Analyst & Trader
**Objective:** Analyze the provided betting market data to deliver actionable insights, identify mispricings, and perform scenario analysis.
**Current Date:** Monday, August 24, 2026
**Context:** Prediction markets (Polymarket/Kalshi) are binary option markets where price (1-99) equals implied probability (1%-99%).

---

## 1. Event Snapshot
**Event:** Will the FDA approve gedatolisib for advanced breast cancer?
**Category:** Science and Technology | **Status:** active
**Resolution Date:** N/A (Unknown)
**Time Pressure:** Unknown

**Description:** gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer

If the FDA approves gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer for marketing before X 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application, NDA, or Biologics License Application, BLA, For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA, sNDA, or supplemental BLA, sBLA, for the sp

**Resolution Criteria (Sample):**
"If the FDA approves gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer for marketing before Jul 1, 2027, then the market resolves to Yes. Secondary rules: An approval is defined as:

For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics Licen"

## 2. Market liquidity & Volume
* **Total Volume:** $0
* **Total Liquidity:** $0
* **Activity Level:** Low Activity (Vol/Liq Ratio: 0.00)

## 3. Market Data (Prices & Odds)
### 1. Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jul 1, 2027?
- **Kalshi** (End: Jul 8, 2027): Vol $0
  DATA: [Yes: 87.0% (0.0%)] | [No: 13.0% (0.0%)]

### 2. Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jan 1, 2027?
- **Kalshi** (End: Jan 8, 2027): Vol $0
  DATA: [Yes: 78.5% (0.0%)] | [No: 21.5% (0.0%)]

### 3. Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Oct 1, 2026?
- **Kalshi** (End: Oct 8, 2026): Vol $0
  DATA: [Yes: 78.0% (0.0%)] | [No: 22.0% (0.0%)]

### 4. Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Aug 1, 2026?
- **Kalshi** (End: Aug 8, 2026): Vol $0
  DATA: [Yes: 85.0% (0.0%)] | [No: 15.0% (0.0%)]

---

## Analysis Instructions
Please provide a structured analysis using the following template:

### 1. Executive Summary
*   **Verdict:** [Most Likely Outcome]
*   **Confidence:** [0-100]%
*   **Timeframe:** [Immediate / Short-term / Long-term]
*   **Actionable Trade:** [Buy YES / Buy NO / Stay Away] (Include entry price target if applicable)
*   **Rationale:** 2-sentence summary of the core thesis.

### 2. Scenario Analysis
*   **Bull Case (Why YES goes up):** List specific catalysts or data points.
*   **Bear Case (Why YES goes down):** List specifics.
*   **Invalidation Point:** What happens to prove your thesis wrong?

### 3. Market Mechanics & Risks
*   **Liquidity/Volume Analysis:** Is the market efficient? Is it easy to exit?
*   **Cross-Platform Arbitrage:** (If applicable) Is the spread tradeable after fees?
*   **Time Decay:** How does time passing affect this position?

### 4. Signal Scores (0-100)
*   **Momentum:** [Score] (Price trend & velocity)
*   **Conviction:** [Score] (Volume backing the move)
*   **Information Edge:** [Score] (Likelihood of non-public info affecting price)
*   **Risk/Reward:** [Score] (Potential upside vs downside)

**Constraints:**
- Be direct and objective.
- Use bullet points for readability.
- If data is conflicting or insufficient, explicitly state "Low Confidence".

Tap text to select all

Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.

KALSHIScience and Technology

Will the FDA approve gedatolisib for advanced breast cancer?

Volume$0.00

Markets4

4 of 4

Sort:

KALSHI

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jul 1, 2027?

KALSHI

KKalshi

Yes 87.0¢No 13.0¢

KALSHIHealth

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jul 1, 2027?

If the FDA approves gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer for marketing before Jul 1, 2027, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics Licen

KALSHI

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Aug 1, 2026?

KALSHI

KKalshi

Yes 85.0¢No 15.0¢

KALSHIHealth

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Aug 1, 2026?

If the FDA approves gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer for marketing before Aug 1, 2026, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics Licen

KALSHI

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jan 1, 2027?

KALSHI

KKalshi

Yes 78.5¢No 21.5¢

KALSHIHealth

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jan 1, 2027?

If the FDA approves gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer for marketing before Jan 1, 2027, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics Licen

KALSHI

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Oct 1, 2026?

KALSHI

KKalshi

Yes 78.0¢No 22.0¢

KALSHIHealth

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Oct 1, 2026?

If the FDA approves gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer for marketing before Oct 1, 2026, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics Licen

No related news found

Discussion

0 Comments

Market Insights

Average Yes Price

82¢

Kalshi

Arbitrage Opps

Cross-Platform

Embed Widget

Add this market to your website

Volume

Platforms

HTML

<iframe src="https://predictpedia.com/embed/plr7Jx" width="400" height="160" frameborder="0" style="border-radius: 8px; max-width: 100%;" title="Will the FDA approve gedatolisib for advanced breast cancer?"></iframe>

Trade This Market

Trade on Kalshi

Will the FDA approve gedatolisib for advanced breast cancer?

Will the FDA approve gedatolisib for advanced breast cancer?

Platform StatsQuick Platform Comparison

Price ChartMatched Markets Price Graph

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jul 1, 2027?

AI Analysis

About This Event

Custom AI Analysis Prompt

Educational Context

Events (1)

Will the FDA approve gedatolisib for advanced breast cancer?

Markets (4)

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jul 1, 2027?

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jul 1, 2027?

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Aug 1, 2026?

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Aug 1, 2026?

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jan 1, 2027?

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jan 1, 2027?

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Oct 1, 2026?

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Oct 1, 2026?

Related News & Context

Discussion

Market Insights

Share

Embed Widget

Trade This Market

Platform StatsQuick Platform Comparison

Price ChartMatched Markets Price Graph

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jul 1, 2027?

Custom AI Analysis Prompt

Will the FDA approve gedatolisib for advanced breast cancer?

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jul 1, 2027?

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jul 1, 2027?

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Aug 1, 2026?

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Aug 1, 2026?

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jan 1, 2027?

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jan 1, 2027?

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Oct 1, 2026?

Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Oct 1, 2026?

Related News & Context

Discussion

Share

Embed Widget